Management of Primary Small-Vessel Vasculitis

Crystal E. Nwannunu, BS; Radhika Shah, BS, MS; Allison L. Limmer, BS, BA; Ravi R. Patel, MD; Uyen Ngoc Mui, MD; Stephen K. Tyring, MD


Skin Therapy Letter. 2020;25(3):5-8. 

In This Article


The SVV are a heterogenous group of diseases that include eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, microscopic polyangiitis, IgA vasculitis, and cryoglobulinemic vasculitis. These disorders can arise without obvious cause or in the setting of autoimmune disease or infection. Clinical manifestations are broad, but often involve cutaneous findings such as purpura and petechiae that can distress affected patients. Effective therapy is founded upon adequate management of the vasculitis primarily via immunomodulation as well as identification and control of modifiable risk factors such as diabetes, hypercholesterolemia, and tobacco use. SVV have the potential to be impacted by emerging immunotherapeutic interventions, especially biologic agents targeting B- and T-cells; however, additional research is needed in this area.